市場調查報告書
商品編碼
1086992

器官移植的全球市場預測(2022年∼2027年)

Global Organ Transplant Market - Forecasts from 2022 to 2027

出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 120 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球器官移植的市場規模,2020年為189億8,700萬美金,在預測期間內預計以8.51%的年複合成長率發展,預計至2027年達到336億3,100萬美元。該市場擴大的主要原因,是為了治療器官功能衰竭的創新組織移植產品及器官移植的需求高漲。

本報告提供全球器官移植市場調查,市場規模和預測,市場促進因素及課題,市場趨勢,各產品類型、內臟器官的各類型、各終端用戶、各地區的市場分析,競爭情形,主要企業的簡介等系統性資訊。

目錄

第1章 簡介

  • 市場定義
  • 市場區隔

第2章 調查手法

  • 調查資料
  • 前提條件

第3章 摘要整理

  • 調查的重點

第4章 市場動態

  • 推動市場要素
  • 阻礙市場要素
  • 波特的五力分析
    • 供給企業談判力
    • 買主談判力
    • 替代品的威脅
    • 新加入業者的威脅
    • 競爭企業間的敵對關係
  • 產業的價值鏈分析

第5章 全球器官移植市場:各產品類型

  • 簡介
  • 內臟器官保存解決方案
  • 移植診斷
  • 組織產品
  • 其他

第6章 全球器官移植市場:內臟器官的各類型

  • 簡介
  • 心臟
  • 肝臟
  • 肝臟
  • 胰臟

第7章 全球器官移植市場:各終端用戶

  • 簡介
  • 醫院
  • 移植中心
  • 其他

第8章 全球器官移植市場:各地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 其他
  • 中東、非洲
    • 沙烏地阿拉伯
    • 以色列
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 印尼
    • 泰國
    • 台灣
    • 其他

第9章 競爭環境與分析

  • 主要企業策略分析
  • 新興企業和市場收益性
  • 合併,收購,協定,及合作
  • 供應商競爭力矩陣

第10章 企業簡介

  • OrganOx Limited
  • GlaxoSmithKline Plc.
  • Pfizer
  • Organ Assist B.V.
  • Paragonix Technologies Inc.
  • Novartis AG
  • Preservation Solution Inc.
  • Water Medical System LLC
  • Sanofi S.A
  • XVIVO Perfusion AB
  • Bridge to Life Ltd.
目錄
Product Code: KSI061612957

The global organ transplant market is projected to grow at a CAGR of 8.51% during the forecast period to reach US$33.631 billion by 2027, from US$18.987 billion in 2020.

A major element driving market expansion is the rising need for innovative tissue transplantation products and organ transplantation to treat organ failure. Organ failure can be caused by several reasons, including severe trauma, poor eating habits, excessive alcohol intake, poisoning, blood loss, drug misuse, and other acute disorders. Diabetes and high blood pressure, for example, are the most common causes of end-stage kidney disease, which requires a renal transplant or dialysis to keep a patient alive. The need for tissue and organ transplantation, particularly kidney, heart, liver, and lungs transplantation, is quite high worldwide. In 2019, around 122,913 people were waiting for organ transplants in the United States, according to the US Department of Health and Human Services.

The market is also being boosted by the launch of technologically improved products and an increase in the number of tissue banks. According to the US Department of Health and Human Services, 43,201 people in the US were waiting for kidney transplants in 2019, although only 23,401 kidney transplants were carried out. Furthermore, recipients are prescribed potent immunosuppressive medicines following transplantation surgery, increasing their susceptibility to infectious infections as their immune is reduced. Technological advancements in novel transplant products and methods by biotechnology and medical device companies and rising healthcare spending are expected to boost the market.

Another factor driving the market is an increase in the prevalence of acute diseases like diabetes and high blood pressure that lead to end-stage renal disease. According to the World Health Organization (WHO), the geriatric population will exceed 2 billion by 2050. Liver, lung and kidney failures, cardiovascular illnesses, and other conditions are becoming increasingly common as a result of the rising prevalence of chronic diseases. This is a significant factor driving organ care product demand. Cirrhosis is the eleventh largest cause of death globally, and liver cancer is the sixteenth leading cause of death, according to the European Association for the Study of Liver.

However, limitations, such as a scarcity of organ donors for transplantation and high costs, are projected to limit market expansion. The need for organ care is being hampered by the high expense of therapy. The lengthy clearance process for novel organ care products hinders the organ care market's growth. The market's expansion is being hampered by a scarcity of trained specialists in the organ care system. Transplanting a human organ is a very sophisticated surgery requiring outstanding abilities. Because there are so few surgeons in this field who can perform these types of procedures, the cost of this procedure is extremely high. This aspect can potentially stifle the expansion of the organ transplantation market significantly. Furthermore, the number of organ donors is insignificant compared to the number of persons who require such organs. Another key aspect that may stymie the expansion of the organ transplantation market is the rising incidence of organ failure.

Key Developments

In December 2021, Penn Medicine announced that it had received a seven-year, $14 million grant from the National Institutes of Health (NIH) to apply chimeric antigen receptor T-cell immunotherapies to identify and treat patients in need of kidney transplants. OrganOx Limited debuted its ground-breaking liver perfusion equipment in January 2019. It was also given the green light by the UK's National Institute for Health and Care Excellence.

By product type, the global organ transplant market can be segmented into organ preservation solutions, transplant diagnostics, tissue products, and others. The tissue products category is expected to dominate the market. The segment's growth is fueled by rising demand for transplant operations such as cochlear implants, orthopedic soft tissues, heart valves, and bone marrow.

By organ type, the global organ transplant market can be segmented into heart, intestine, kidney, liver, lung, and pancreas. Renal or kidney transplantation is the most prevalent type of organ transplantation worldwide. Although various treatments for end-stage renal disease, such as dialysis, are available, kidney transplantation is widely regarded as the best option.

By end-users, the global organ transplant market can be segmented into transplant centers, hospitals, and others. The hospital's category accounted for the greatest proportion owing to the significant number of organ and tissue transplant procedures performed at hospitals. However, due to the rising demand for healthcare facilities that cater to patients' unmet requirements and government programs encouraging organ donation, the transplant centers category is likely to increase over the projection period.

By geography, the global organ transplant market can be segmented into the Asia Pacific, North America, the Middle East and Africa, South America, and Europe. Over the projected period, the Asia Pacific region is expected to grow at the highest rate. The developing medical tourism in Asia Pacific countries such as India, the growing geriatric population in various nations, and the rising prevalence of congenital hydrocephalus in China are all factors driving revenue growth in this regional market.

COVID-19 Insights

Access to solid organ transplantation has been hampered by the COVID-19 epidemic. During the epidemic, the number of transplants performed decreased globally. The most afflicted organ transplants were kidneys, followed by the lungs, liver, and heart. COVID-19 had a global impact on transplantation, with a 31% decline in solid organ transplants conducted during the first pandemic wave compared to the previous year. Approximately 48,000 years of patient life were lost as a result of this deterioration.

Market Segmentation:

  • By Product Type

Organ preservation solutions

Transplant diagnostics

Tissue products

Others

  • By Organ Type

Heart

Intestine

Kidney

Liver

Lung

Pancreas

  • By End-Users

Hospitals

Transplant Centers

Others

  • By Geography

North America

  • USA
  • Canada
  • Mexico

South America

  • Brazil
  • Argentina
  • Others

Europe

  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Middle East and Africa

  • Saudi Arabia
  • Israel
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Taiwan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Definition
  • 1.2. Market Segmentation

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Powers of Buyers
    • 4.3.3. Threat of Substitutes
    • 4.3.4. Threat of New Entrants
    • 4.3.5. Competitive Rivalry in Industry
  • 4.4. Industry Value Chain Analysis

5. GLOBAL ORGAN TRANSPLANT MARKET, BY PRODUCT TYPE 

  • 5.1. Introduction
  • 5.2. Organ preservation solutions
  • 5.3. Transplant diagnostics
  • 5.4. Tissue products
  • 5.5. Others

6. GLOBAL ORGAN TRANSPLANT MARKET, BY ORGAN TYPE

  • 6.1. Introduction
  • 6.2. Heart 
  • 6.3. Intestine 
  • 6.4. Kidney
  • 6.5. Liver
  • 6.6. Lung 
  • 6.7. Pancreas

7. GLOBAL ORGAN TRANSPLANT MARKET, BY END-USERS 

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Transplant Centers
  • 7.4. Others

8. GLOBAL ORGAN TRANSPLANT MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom 
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Italy
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. Israel
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. Japan
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Taiwan 
    • 8.6.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisition, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES 

  • 10.1. OrganOx Limited
  • 10.2. GlaxoSmithKline Plc.
  • 10.3. Pfizer
  • 10.4. Organ Assist B.V.
  • 10.5. Paragonix Technologies Inc. 
  • 10.6. Novartis AG
  • 10.7. Preservation Solution Inc.
  • 10.8. Water Medical System LLC
  • 10.9. Sanofi S.A
  • 10.10. XVIVO Perfusion AB
  • 10.11. Bridge to Life Ltd.